A Prospective, Multicenter Phase II Study of Consolidation with Cyclophosphamide, Bortezomib and Dexamethasone (CVD) in Patients with Multiple Myeloma after Autologous Stem Cell Transplantation; the KMM130 Study

The three-drug combination of cyclophosphamide, bortezomib and dexamethasone (CVD) has shown significant efficacy and manageable toxicity as induction therapy in patients with multiple myeloma (MM). The Korean Multiple Myeloma Working Party (KMMWP) decided to evaluate the efficacy and toxicity of CVD as consolidation therapy following autologous stem cell transplantation (ASCT). Method: In this phase II study, 46 patients achieving very good partial response (VGPR) or partial response (PR) after ASCT were initially enrolled. Of whom, 42 patients completed three courses of CVD consisting of cyclophosphamide 300mg/m2 orally on days 1, 8, 15 and bortezomib 1.3mg/m2 subcutaneously on days 1, 8, 15 and 22, along with dexamethasone 20mg per mouth on days 1-2, 8-9, 15-16 and 22-23.